Bio-Path Holdings, Inc. (BPTH)
| Market Cap | 6.71M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -16.67M |
| Shares Out | 12.35M |
| EPS (ttm) | -2.04 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 129,448 |
| Open | 0.529 |
| Previous Close | 0.569 |
| Day's Range | 0.505 - 0.543 |
| 52-Week Range | 0.320 - 2.350 |
| Beta | 0.97 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 15, 2023 |
About BPTH
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also d... [Read more]
Financial Performance
Financial StatementsNews
Bio-Path Holdings Reports Third Quarter 2023 Financial Results
HOUSTON, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop ...
Bio-Path Holdings to Announce Third Quarter 2023 Financial Results on November 15, 2023
HOUSTON, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a por...
Bio-Path Holdings to Host Virtual Key Opinion Leader Event to Discuss Prexigebersen and Advances in the Treatment Landscape for Acute Myeloid Leukemia
Conference call to be held on Monday, October 30, 2023 at 9:00 a.m. ET Conference call to be held on Monday, October 30, 2023 at 9:00 a.m. ET
Bio-Path Holdings to Present at H.C. Wainwright 25th Annual Global Investment Conference
HOUSTON, Sept. 08, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop...
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q2 23
Dallas, Texas--(Newsfile Corp. - August 30, 2023) - Bio-Path Holdings, Inc. (NASDAQ: BPTH): Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH) for Q2 2023. The full ...
Bio-Path Holdings Reports Second Quarter 2023 Financial Results
HOUSTON, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop ...
Bio-Path Holdings to Announce Second Quarter 2023 Financial Results on August 15, 2023
HOUSTON, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a po...
Bio-Path Holdings, Inc. Announces Pricing of $2.1 Million Public Offering
HOUSTON, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (Nasdaq:BPTH) (“Bio-Path” or the “Company”), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanopartic...
Bio-Path Holdings Announces Positive Results from Interim Analysis of Phase 2 Clinical Trial of Prexigebersen in Acute Myeloid Leukemia
Interim Data Analysis Demonstrates Significant Clinical Improvement and Tolerable Safety Profile in High-Risk Patients
Bio-Path Holdings Announces Successful Completion of First Dose Cohort in Phase 1/1b Clinical Trial of BP1001-A in Solid Tumors
Advancing to Second Cohort of Phase 1/1b Clinical Trial Evaluating BP1001-A to Treat Patients with Solid Tumors, Including Ovarian, Endometrial, Pancreatic and Breast Cancer Advancing to Second Cohort...
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q1 23
Dallas, Texas--(Newsfile Corp. - June 2, 2023) - Bio-Path Holdings, Inc. (NASDAQ: BPTH): Stonegate Capital Partners updates coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH). The full report can be a...
Bio-Path Holdings Reports First Quarter 2023 Financial Results
HOUSTON, May 12, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a...
Bio-Path Holdings to Announce First Quarter 2023 Financial Results on May 12, 2023
HOUSTON, May 05, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a port...
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q4 '22
Dallas, Texas--(Newsfile Corp. - April 10, 2023) - Bio-Path Holdings, Inc. (NASDAQ: BPTH): The full report can be accessed by clicking on the following link: https://stonegateinc.com/reports/BPTH_Q422...
Bio-Path Holdings Reports Full Year 2022 Financial Results
Conference Call to be Held Today at 8:30 A.M. ET Conference Call to be Held Today at 8:30 A.M. ET
Bio-Path Holdings to Announce Fourth Quarter and Full Year 2022 Financial Results on March 31, 2023
HOUSTON, March 24, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc. (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a po...
Bio-Path Holdings Provides Clinical and Operational Update
Company Expects to Achieve Several Near-Term Clinical Milestones Company Expects to Achieve Several Near-Term Clinical Milestones
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q3 '22
Dallas, Texas--(Newsfile Corp. - December 19, 2022) - Bio-Path Holdings, Inc. (NASDAQ: BPTH): Stonegate Capital Partners updates coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH). The full report can...
Bio-Path Holdings Announces First Patient Dosed in Phase 1/1b Clinical Trial of BP1001-A in Solid Tumors
Phase 1/1b Clinical Trial Evaluating Ability of BP1001-A to Treat Patients with Solid Tumors, Including Ovarian, Endometrial, Pancreatic and Breast Cancer Phase 1/1b Clinical Trial Evaluating Ability ...
Bio-Path Holdings Reports Third Quarter 2022 Financial Results
Conference Call to be Held Today at 8:30 A.M. ET Conference Call to be Held Today at 8:30 A.M. ET
Bio-Path Holdings to Announce Third Quarter 2022 Financial Results on November 15, 2022
HOUSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a por...
Bio-Path Holdings, Inc. Announces $2.0 Million Registered Direct Offering and Concurrent Private Placement
HOUSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop ...
Bio-Path Holdings Announces First Patient Dosed in Phase 1/1b Study of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia Patients
BP1002 Offers Unique Opportunity for Venetoclax-Resistant Patients by Utilizing RNAi to Limit Cell's Ability to Produce Bcl-2 Protein BP1002 Offers Unique Opportunity for Venetoclax-Resistant Patients...
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH)
Dallas, Texas--(Newsfile Corp. - September 30, 2022) - Bio-Path Holdings, Inc. (Nasdaq: BPTH): The full report can be accessed by clicking on the following link: https://stonegateinc.com/reports/BPTH_...
Bio-Path Holdings to Present at H.C. Wainwright 24th Annual Global Investment Conference
HOUSTON, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a po...